Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 300

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 300
---
 and restated articles
of association to be in effect upon completion of this offering permit us to exculpate, indemnify and insure our office holders to the
fullest extent permitted by the Companies Law and Securities Law. Each of our office holders have entered into an indemnification agreement
exculpating them, to the fullest extent permitted by Israeli law, from liability to us for damages caused to us as a result of a breach
of the duty of care and undertaking to indemnify them to the fullest extent permitted by Israeli law, including with respect to liabilities
resulting from certain acts performed by such office holders in their capacity as an office holder of the Company, our subsidiaries or
our affiliates. The indemnification is limited both in terms of amount and coverage.

In the opinion of the SEC,
indemnification of directors and office holders for liabilities arising under the Securities Act, however, is against public policy and
therefore unenforceable.

<div align='center'>II-2</div>

Item 7. Recent Sales of Unregistered Securities.

The following list sets forth
information as to all securities we have sold since January 2022, which were not registered under the Securities Act.

Between August 2020 and February
2021, we entered into several convertible loan agreements for total consideration of $900,000, or the 2020 CLAs. In October 2024, we proposed
to the lenders under the 2020 CLAs to increase the principal amount under their respective portion of the 2020 CLA, up to an additional
aggregate amount of US$ 340,000, or the October 2024 Addendum, so that the 2020 CLAs shall bear interest at 8% per annum until maturity
commencing as of July 1, 2024 with respect to non-participating lenders and March 31, 2025 with respect to participating lenders. In addition,
pursuant to the October 2024 Addendum, upon the occurrence of an initial public offering based on a pre money valuation of $5.15 million,
the 2020 CLAs shall be automatically converted into 243,955 Ordinary Shares and the Additional Amount in addition to the Risk Premium
(each as defined therein) shall be automatically converted into 221,456 Ordinary Shares, which will occur upon the completion of this
offering. As of November 20, 2024, the Company received $337,500 out of the $450,000